CHARLES RIVER LABORATORIES INC
10-Q, EX-27.1, 2000-11-07
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CHARLES RIVER LABORATORIES INC, 10-Q, 2000-11-07
Next: VEGA ATLANTIC CORP/CO, PRES14A, 2000-11-07



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM THE CONSOLIDATED
STATEMENT OF EARNINGS FOR THE NINE MONTHS ENDED SEPTEMBER 23, 2000 AND THE
CONSOLIDATED BALANCE SHEEET AT SEPTEMBER 23, 2000 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          OCT-30-2000
<PERIOD-END>                               SEP-23-2000
<CASH>                                          28,008
<SECURITIES>                                         0
<RECEIVABLES>                                   49,170
<ALLOWANCES>                                       876
<INVENTORY>                                     31,544
<CURRENT-ASSETS>                               114,275
<PP&E>                                         257,509
<DEPRECIATION>                                 142,825
<TOTAL-ASSETS>                                 395,267
<CURRENT-LIABILITIES>                           60,551
<BONDS>                                        202,222
                                0
                                          0
<COMMON>                                             1
<OTHER-SE>                                      99,237
<TOTAL-LIABILITY-AND-EQUITY>                   395,267
<SALES>                                        215,772
<TOTAL-REVENUES>                               215,772
<CGS>                                          126,379
<TOTAL-COSTS>                                  126,379
<OTHER-EXPENSES>                                25,881
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              26,956
<INCOME-PRETAX>                                 25,412
<INCOME-TAX>                                     6,877
<INCOME-CONTINUING>                             18,535
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  8,445
<CHANGES>                                            0
<NET-INCOME>                                     9,841
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission